Estradiol modulation of cortical, striatal and raphe nucleus 5-HT 1A and 5-HT2A receptors of female hemiparkinsonian monkeys after long-term ovariectomy

Neuropharmacology

Volumn 60, Issue 4, 2011, Pages 642-652

  Sánchez, Maria Gabriela ^a,b   Estrada Camarena, Erika ^a,b   Bélanger, Nancy ^a,b   Morissette, Marc ^a,b   Di Paolo, Thérse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

5 HT receptors; Depression; Estrogen; MPTP monkey; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ESTRADIOL; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KETANSERIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN DAMAGE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; FEMALE; FRONTAL CORTEX; HAPLORHINI; HEMISPHERE; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OVARIECTOMY; PARKINSON DISEASE; PARKINSONISM; POSTMENOPAUSE; PRIORITY JOURNAL; RAPHE NUCLEUS; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; TREATMENT DURATION;

ANIMALS; AUTORADIOGRAPHY; CEREBRAL CORTEX; CORPUS STRIATUM; ESTRADIOL; ESTROGENS; FEMALE; MACACA FASCICULARIS; OVARIECTOMY; PARKINSON DISEASE, SECONDARY; RAPHE NUCLEI; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A;

EID: 79251599414     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.11.024     Document Type: Article

References (96)

1. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, H. Black, D. Bonds, R. Brunner, R. Brzyski, B. Caan, R. Chlebowski, D. Curb, M. Gass, J. Hays, G. Heiss, S. Hendrix, B.V. Howard, J. Hsia, A. Hubbell, R. Jackson, K.C. Johnson, H. Judd, J.M. Kotchen, L. Kuller, A.Z. LaCroix, D. Lane, R.D. Langer, N. Lasser, C.E. Lewis, J. Manson, K. Margolis, J. Ockene, M.J. O'Sullivan, L. Phillips, R.L. Prentice, C. Ritenbaugh, J. Robbins, J.E. Rossouw, G. Sarto, M.L. Stefanick, L. Van Horn, J. Wactawski-Wende, R. Wallace, and S. Wassertheil-Smoller Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial Jama 291 2004 1701 1712
2. N. Belanger, L. Gregoire, P. Bedard, and T. Di Paolo Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys Endocrine 21 2003 97 101
3. N. Belanger, L. Gregoire, A. Hadj Tahar, and P.J. Bedard Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys Mov. Disord. 18 2003 1436 1441
4. C.L. Bethea, A.P. Reddy, Y. Tokuyama, J.A. Henderson, and F.B. Lima Protective actions of ovarian hormones in the serotonin system of macaques Front. Neuroendocrinol. 30 2009 212 238
5. P.J. Blanchet, J. Fang, K. Hyland, L.A. Arnold, M.M. Mouradian, and T.N. Chase Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study Neurology 53 1999 91 95
6. P. Blier Altered function of the serotonin 1A autoreceptor and the antidepressant response Neuron 65 2010 1 2
7. P. Blier, and F.V. Abbott Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain J. Psychiatry Neurosci. 26 2001 37 43
8. 11C]DASB Mov. Disord. 23 2008 1776 1780
9. J.G. Buckwalter, F.Z. Stanczyk, C.A. McCleary, B.W. Bluestein, D.K. Buckwalter, K.P. Rankin, L. Chang, and T.M. Goodwin Pregnancy, the postpartum, and steroid hormones: effects on cognition and mood Psychoneuroendocrinology 24 1999 69 84
10. G.A. Carrasco, S.A. Barker, Y. Zhang, K.J. Damjanoska, N.R. Sullivan, F. Garcia, D.N. D'Souza, N.A. Muma, and L.D. van De Kar Estrogen treatment increases the levels of regulator of G protein signaling-Z1 in the hypothalamic paraventricular nucleus: possible role in desensitization of 5-hydroxytryptamine1A receptors Neuroscience 127 2004 261 267
11. P. Celada, M. Puig, M. Amargos-Bosch, A. Adell, and F. Artigas The therapeutic role of 5-HT1A and 5-HT2A receptors in depression J. Psychiatry Neurosci. 29 2004 252 265
12. C.P. Chen, J.T. Alder, L. Bray, A.E. Kingsbury, P.T. Francis, and O.J. Foster Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex Ann. N. Y. Acad. Sci. 861 1998 288 289
13. B. Cholerton, C.E. Gleason, L.D. Baker, and S. Asthana Estrogen and Alzheimer's disease: the story so far Drugs Aging 19 2002 405 427
14. L.S. Cohen, C.N. Soares, J.R. Poitras, J. Prouty, A.B. Alexander, and J.L. Shifren Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report Am. J. Psychiatry 160 2003 1519 1522
15. A. Costa, A. Peppe, G.A. Carlesimo, P. Pasqualetti, and C. Caltagirone Major and minor depression in Parkinson's disease: a neuropsychological investigation Eur. J. Neurol. 13 2006 972 980
16. M. Cyr, R. Bosse, and T. Di Paolo Gonadal hormones modulate 5-hydroxytryptamine2A receptors: emphasis on the rat frontal cortex Neuroscience 83 1998 829 836
17. M. Cyr, F. Calon, M. Morissette, and T. Di Paolo Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease J. Psychiatry Neurosci. 27 2002 12 27
18. J.F. Cryan, and B.E. Leonard 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response Hum. Psychopharmacol. 15 2000 113 135
19. D.C. Deecher Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms Expert Opin. Investig. Drugs 14 2005 435 448
20. E. Estrada-Camarena, A. Fernandez-Guasti, and C. Lopez-Rubalcava Interaction between estrogens and antidepressants in the forced swimming test in rats Psychopharmacology (Berl) 173 2004 139 145
21. E. Estrada-Camarena, A. Fernandez-Guasti, and C. Lopez-Rubalcava Participation of the 5-HT1A receptor in the antidepressant-like effect of estrogens in the forced swimming test Neuropsychopharmacology 31 2006 247 255
22. E. Estrada-Camarena, C. Lopez-Rubalcava, N. Vega-Rivera, S. Recamier-Carballo, and A. Fernandez-Guasti Antidepressant effects of estrogens: a basic approximation Behav. Pharmacol. 21 2010 451 464
23. E. Estrada-Camarena, N.M. Rivera, C. Berlanga, and A. Fernandez-Guasti Reduction in the latency of action of antidepressants by 17 beta-estradiol in the forced swimming test Psychopharmacology (Berl) 201 2008 351 360
24. C. Faure, O. Mnie-Filali, H. Scarna, G. Debonnel, and N. Haddjeri Effects of the 5-HT7 receptor antagonist SB-269970 on rat hormonal and temperature responses to the 5-HT1A/7 receptor agonist 8-OH-DPAT Neurosci. Lett. 404 2006 122 126
25. G. Fink Hormones and mental disorders-focus on estrogen-serotonin interactions Eur. Psychiatry 17 Suppl. 1 2002 42
26. D. Frechilla, A. Cobreros, L. Saldise, R. Moratalla, R. Insausti, M. Luquin, and J. Del Rio Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys Synapse 39 2001 288 296
27. M. Gass Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy Cleve. Clin. J. Med. 75 Suppl. 4 2008 S13 S16
28. C.E. Gleason, C.M. Carlsson, S. Johnson, C. Atwood, and S. Asthana Clinical pharmacology and differential cognitive efficacy of estrogen preparations Ann. N. Y. Acad. Sci. 1052 2005 93 115
29. C.E. Gleason, B. Cholerton, C.M. Carlsson, S.C. Johnson, and S. Asthana Neuroprotective effects of female sex steroids in humans: current controversies and future directions Cell Mol. Life Sci. 62 2005 299 312
30. A. Gogos, P. Kwek, C. Chavez, and M. van den Buuse Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors J. Pharmacol. Exp. Ther. 333 2010 218 227
31. A. Graziottin, and A. Serafini Depression and the menopause: why antidepressants are not enough? Menopause Int. 15 2009 76 81
32. L. Gregoire, P. Samadi, J. Graham, P.J. Bedard, G.D. Bartoszyk, and T. Di Paolo Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys Parkinsonism Relat. Disord. 15 2009 445 452
33. P.B. Hedlund The 5-HT7 receptor and disorders of the nervous system: an overview Psychopharmacology (Berl) 206 2009 345 354
34. P.B. Hedlund, and J.G. Sutcliffe Functional, molecular and pharmacological advances in 5-HT7 receptor research Trends Pharmacol. Sci. 25 2004 481 486
35. J.A. Henderson, and C.L. Bethea Differential effects of ovarian steroids and raloxifene on serotonin 1A and 2C receptor protein expression in macaques Endocrine 33 2008 285 293
36. P. Huot, T.H. Johnston, L. Winkelmolen, S.H. Fox, and J.M. Brotchie 5-HT(2A) receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA Neurobiol. Aging 2010 Jun 17. [Epub ahead of print]
37. M.W. Jakowec, and G.M. Petzinger 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates Comp. Med. 54 2004 497 513
38. B. Jasinska-Myga, J.D. Putzke, C. Wider, Z.K. Wszolek, and R.J. Uitti Depression in Parkinson's disease Can. J. Neurol. Sci. 37 2010 61 66
39. K.A. Jellinger, and W. Paulus Clinico-pathological correlations in Parkinson's disease Clin. Neurol. Neurosurg. 94 Suppl. 1992 S86 S88
40. V.S. Kostic, F. Agosta, I. Petrovic, S. Galantucci, V. Spica, M. Jecmenica-Lukic, and M. Filippi Regional patterns of brain tissue loss associated with depression in Parkinson disease Neurology 75 2010 857 863
41. A. Kugaya, C.N. Epperson, S. Zoghbi, C.H. van Dyck, Y. Hou, M. Fujita, J.K. Staley, P.K. Garg, J.P. Seibyl, and R.B. Innis Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women Am. J. Psychiatry 160 2003 1522 1524
42. M. Landry, and T. Di Paolo Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor Brain Res. Mol. Brain Res. 112 2003 82 89
43. M. Le Saux, and T. Di Paolo Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene J. Psychiatry Neurosci. 30 2005 110 117
44. Y. Li, X.F. Huang, C. Deng, B. Meyer, A. Wu, Y. Yu, W. Ying, G.Y. Yang, M.A. Yenari, and Q. Wang Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats Synapse 64 2010 224 230
45. A. Lieberman Depression in Parkinson's disease - a review Acta Neurol. Scand. 113 2006 1 8
46. N.Z. Lu, and C.L. Bethea Ovarian steroid regulation of 5-HT1A receptor binding and G protein activation in female monkeys Neuropsychopharmacology 27 2002 12 24
47. R.F. Martin, and D.M. Bowden Primate Brain Maps: Structure of the Macaque Brain 2000 Elsevier Science Amsterdam pp. 1-160
48. H.S. Mayberg, S.E. Starkstein, B. Sadzot, T. Preziosi, P.L. Andrezejewski, R.F. Dannals, H.N. Wagner Jr., and R.G. Robinson Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease Ann. Neurol. 28 1990 57 64
49. R. Mayeux, Y. Stern, J.B. Williams, L. Cote, A. Frantz, and I. Dyrenfurth Clinical and biochemical features of depression in Parkinson's disease Am. J. Psychiatry 143 1986 756 759
50. W.M. McDonald, I.H. Richard, and M.R. DeLong Prevalence, etiology, and treatment of depression in Parkinson's disease Biol. Psychiatry 54 2003 363 375
51. B. McEwen Estrogen actions throughout the brain Recent Prog. Horm. Res. 57 2002 357 384
52. B.S. McEwen Clinical review 108: the molecular and neuroanatomical basis for estrogen effects in the central nervous system J. Clin. Endocrinol. Metab. 84 1999 1790 1797
53. R.M. Miller, and H.J. Federoff Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems Neuroscientist 11 2005 539 549
54. M. Morissette, and T. Di Paolo Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys J. Neurosci. Res. 87 2009 1634 1644
55. E.L. Moses-Kolko, S.L. Berga, P.J. Greer, G. Smith, C. Cidis Meltzer, and W.C. Drevets Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women Fertil. Steril 80 2003 554 559
56. A. Munoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Bjorklund, E. Bezard, and M. Carta Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia Brain 131 2008 3380 3394
57. A. Nicoletti, G. Arabia, P. Pugliese, G. Nicoletti, G. Torchia, F. Condino, L. Morgante, A. Quattrone, and M. Zappia Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial Clin. Neuropharmacol. 30 2007 276 280
58. M.K. Osterlund, D.H. Overstreet, and Y.L. Hurd The flinders sensitive line rats, a genetic model of depression, show abnormal serotonin receptor mRNA expression in the brain that is reversed by 17beta-estradiol Brain Res. Mol. Brain Res. 74 1999 158 166
59. N. Panay, and J.W. Studd The psychotherapeutic effects of estrogens Gynecol. Endocrinol. 12 1998 353 365
60. A. Papageorgiou, and C. Denef Stimulation of growth hormone release by 5-hydroxytryptamine (5-HT) in cultured rat anterior pituitary cell aggregates: evidence for mediation by 5-HT2B, 5-HT7, 5-HT1B, and ketanserin-sensitive receptors Endocrinology 148 2007 4509 4522
61. W. Paulus, and K. Jellinger The neuropathologic basis of different clinical subgroups of Parkinson's disease J. Neuropathol. Exp. Neurol. 50 1991 743 755
62. M. Pecins-Thompson, N.A. Brown, and C.L. Bethea Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques Brain Res. Mol. Brain Res. 53 1998 120 129
63. F. Radja, L. Descarries, K.M. Dewar, and T.A. Reader Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study Brain Res. 606 1993 273 285
64. J. Rao Neurochemistry of Parkinson's disease Handb. Clin. Neurol. 83 2007 153 204
65. S.R. Rapp, M.A. Espeland, S.A. Shumaker, V.W. Henderson, R.L. Brunner, J.E. Manson, M.L. Gass, M.L. Stefanick, D.S. Lane, J. Hays, K.C. Johnson, L.H. Coker, M. Dailey, and D. Bowen Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial Jama 289 2003 2663 2672
66. J.W. Richardson-Jones, C.P. Craige, B.P. Guiard, A. Stephen, K.L. Metzger, H.F. Kung, A.M. Gardier, A. Dranovsky, D.J. David, S.G. Beck, R. Hen, and E.D. Leonardo 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants Neuron 65 2010 40 52
67. H.A. Ring, C.J. Bench, M.R. Trimble, D.J. Brooks, R.S. Frackowiak, and R.J. Dolan Depression in Parkinson's disease. A positron emission study Br. J. Psychiatry 165 1994 333 339
68. W.A. Rocca, J.H. Bower, D.M. Maraganore, J.E. Ahlskog, B.R. Grossardt, M. de Andrade, and L.J. Melton 3rd Increased risk of parkinsonism in women who underwent oophorectomy before menopause Neurology 70 2008 200 209
69. W.A. Rocca, B.R. Grossardt, Y.E. Geda, B.S. Gostout, J.H. Bower, D.M. Maraganore, M. de Andrade, and L.J. Melton 3rd Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy Menopause 15 2008 1050 1059
70. M.A. Rogers, J.L. Bradshaw, C. Pantelis, and J.G. Phillips Frontostriatal deficits in unipolar major depression Brain Res. Bull. 47 1998 297 310
71. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, and J. Ockene Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial Jama 288 2002 321 333
72. M.G. Sanchez, M. Bourque, M. Morissette, and T. Di Paolo Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders CNS Neurosci. Ther. 16 2010 e43 71
73. S.L. Sell, R.M. Craft, P.K. Seitz, S.J. Stutz, K.A. Cunningham, and M.L. Thomas Estradiol-sertraline synergy in ovariectomized rats Psychoneuroendocrinology 33 2008 1051 1060
74. S.I. Sharp, C.G. Ballard, I. Ziabreva, M.A. Piggott, R.H. Perry, E.K. Perry, D. Aarsland, U. Ehrt, J.P. Larsen, and P.T. Francis Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia Dement Geriatr. Cogn. Disord. 26 2008 330 338
75. B.B. Sherwin Estrogen and cognitive functioning in women Endocr. Rev. 24 2003 133 151
76. B.B. Sherwin The critical period hypothesis: can it explain discrepancies in the oestrogen-cognition literature? J. Neuroendocrinol. 19 2007 77 81
77. S. Shimohama, H. Sawada, Y. Kitamura, and T. Taniguchi Disease model: Parkinson's disease Trends Mol. Med. 9 2003 360 365
78. B.T. Shireman, P. Bonaventure, and N.I. Carruthers Chapter 2. Recent advances on the 5-HT5A, 5-HT6 and 5-HT7 receptors Annual Reports in Medicinal Chemistry 2008 Academic New York 25 42
79. L.M. Shulman Gender differences in Parkinson's disease Gend. Med. 4 2007 8 18
80. S.A. Shumaker, C. Legault, S.R. Rapp, L. Thal, R.B. Wallace, J.K. Ockene, S.L. Hendrix, B.N. Jones 3rd, A.R. Assaf, R.D. Jackson, J.M. Kotchen, S. Wassertheil-Smoller, and J. Wactawski-Wende Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial Jama 289 2003 2651 2662
81. A. Siddiqui, M. Abu-Amara, C. Aldairy, J.J. Hagan, and C. Wilson 5-HT7 receptor subtype as a mediator of the serotonergic regulation of luteinizing hormone release in the zona incerta Eur. J. Pharmacol. 491 2004 77 84
82. R.J. Smeyne, and V. Jackson-Lewis The MPTP model of Parkinson's disease Brain Res. Mol. Brain Res. 134 2005 57 66
83. C.N. Soares, O.P. Almeida, H. Joffe, and L.S. Cohen Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial Arch. Gen. Psychiatry 58 2001 529 534
84. 35S]GTPgammaS Brain Res. Brain Res. Rev. 38 2001 149 164
85. J. Studd, and N. Panay Are oestrogens useful for the treatment of depression in women? Best Pract. Res. Clin. Obstet. Gynaecol. 23 2009 63 71
86. B.E. Sumner, K.E. Grant, R. Rosie, C. Hegele-Hartung, K.H. Fritzemeier, and G. Fink Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement Brain Res. Mol. Brain Res. 73 1999 119 128
87. R.L. Tannen, M.G. Weiner, D. Xie, and K. Barnhart Perspectives on hormone replacement therapy: the Women's Health Initiative and new observational studies sampling the overall population Fertil. Steril 90 2008 258 264
88. D.R. Thomas, S.A. Gittins, L.L. Collin, D.N. Middlemiss, G. Riley, J. Hagan, I. Gloger, C.E. Ellis, I.T. Forbes, and A.M. Brown Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719 Br. J. Pharmacol. 124 1998 1300 1306
89. D.R. Thomas, and J.J. Hagan 5-HT7 receptors Curr. Drug Targets CNS Neurol. Disord. 3 2004 81 90
90. K.L. Tsang, S.L. Ho, and S.K. Lo Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations Neurology 54 2000 2292 2298
91. C. Veazey, S.O. Aki, K.F. Cook, E.C. Lai, and M.E. Kunik Prevalence and treatment of depression in Parkinson's disease J. Neuropsychiatry Clin. Neurosci. 17 2005 310 323
92. A.A. Walf, J.J. Paris, and C.A. Frye Chronic estradiol replacement to aged female rats reduces anxiety-like and depression-like behavior and enhances cognitive performance Psychoneuroendocrinology 34 2009 909 916
93. M. Wood, M. Chaubey, P. Atkinson, and D.R. Thomas Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT(7) receptor Eur. J. Pharmacol. 396 2000 1 8
94. M. Yamamoto Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background J. Neurol. 248 Suppl. 3 2001 III5 11
95. R.F. Zec, and M.A. Trivedi The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review Neuropsychol. Rev. 12 2002 65 109
96. X. Zhang, P.E. Andren, and P. Svenningsson Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model Physiol. Behav. 92 2007 29 33